专题：中信证券2025年资本市场论坛：砥砺开新局 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 地缘政治环境方面，短期来看，中美关税战阶段性缓和，8月可能是中美博弈走向的下一个关键时间 点；长期来看，本轮贸易冲突可能使全球产业格局深刻重塑，支撑美元体系的四大根基已出现松动，全 球资产的"再平衡"趋势可能延续。 国内宏观和政策方面，关税风雨欲来，预计短期"抢转口"和"抢出口"可支撑今年外贸韧性，但关税对 PPI的冲击沿着"上中游原材料"到"中下游出口链"传导，价格压力仍十分突出。当前国内大循环存在两 大堵点，一是后疫情时代，我国消费并未出现类似海外的"补缺口式"复苏，未来需出台更多政策以提升 居民消费意愿，并通过多种渠道提供优质消费供给。二是经济发展过程中，部分地方产业投资存在一定 趋同性特征，助长产业结构性矛盾，未来应优化部分地方政府行为，并着力于产业升级和结构调整。应 对全球不确定性，我国需修炼内功，以底线思维谋篇"十五五"开局，不断完善中国经济长期改革的方 向。 责任编辑：杨赐 5月28日-30日，中信证券2025年资本市场论坛于上海举办，会议主题为"砥砺开新局"。中信证券宏观 ...

Core Insights - The 2025 Capital Market Forum hosted by CITIC Securities focuses on the theme "Forge Ahead in a New Era," discussing the mid-term outlook for the US-China economy, global macroeconomic and strategic landscape, as well as the A-share and Hong Kong-US stock markets [1] Group 1: Economic Outlook - CITIC Securities' General Manager, Zou Yingguang, emphasizes that China is responding to external uncertainties with high-quality development, showcasing new policy approaches and a significant improvement in the capital market ecosystem [1] - Chief Economist Mingming notes that the global economy is undergoing deep restructuring, with China's economy showing signs of recovery amidst challenges, including resilient retail consumption and infrastructure investment [2] - The forecast for China's GDP growth in 2025 is around 5.0%, supported by potential fiscal policy enhancements in consumption, social security, and technological innovation [2] Group 2: Market Strategies - The A-share market is expected to maintain a favorable valuation compared to other asset classes, with a predicted downward trend in government bond yields [2] - Chief A-share Strategist Qiu Xiang anticipates a significant upward trend in Chinese equity assets starting in Q4 2025, driven by synchronized economic and policy cycles across major economies [3] - Recommended investment strategies include focusing on long-term trends such as enhancing China's technological capabilities, European defense autonomy, and improving social security to stimulate domestic demand [3][4] Group 3: Global Economic Context - The ongoing trade conflicts are likely to reshape the global industrial landscape, with a trend towards "rebalancing" of global assets [3] - The forum features discussions on various economic hotspots, including macro strategies, US-China relations, trade war implications, energy transitions, and innovations in healthcare and consumption [5]

登录新浪财经APP 搜索【信披】查看更多考评等级 专题：中信证券2025年资本市场论坛：砥砺开新局 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 中信证券2025年资本市场论坛于2025年5月28日在上海开幕，主题为"砥砺开新局"。中信证券总经理邹 迎光发表致辞，中信证券首席经济学家明明、宏观与政策首席分析师杨帆、首席A股策略师裘翔及各行 业首席分析师围绕中美经济、全球宏观与战略格局、A股市场及港美股市场等话题进行展望，探讨多重 变局下的国内外经济破局之路。 邹迎光表示，当前，国际政经形势、中国经济转型、资本市场生态都迎来了全新的阶段。我们需要砥砺 前行，开创新局。 其次，中国政策彰显出新思路，中国科创迎来了新篇章。 一方面，扩大内需成为首要任务，保障民生成为主要政策手段，这些都是新局面下的政策新思路。政府 工作报告将提振消费列为首要任务，明确指出要加快补齐内需尤其是消费短板，使内需成为拉动经济增 长的核心动力与稳定锚。 另一方面，中国新旧动能转换进一步加速，科技创新硕果累累。"人工智能+"成为当前最令人瞩目的创 新方向，AI大模型、具身智能等领域爆款频现，这标志着中国企业在本轮科 ...

2025 年以来，黄金与美股的走势呈现出显著的分化与联动特征，两者的博弈背后折射出全球经济秩序的深刻变迁。黄金在突破 3500 美元 / 盎司后剧烈震 荡，而美股则在关税冲击与衰退预期中艰难前行，这种分化既是短期情绪的宣泄，更是长期结构性矛盾的集中爆发。 近期黄金市场的剧烈波动，本质上是多重力量角力的结果。4 月国际金价突破 3500 美元 / 盎司后，5 月出现 7% 的回调，但随后又迅速反弹至 3380 美元， 显示多空博弈的白热化。这种波动背后存在三重逻辑： 中东局势升级、俄乌冲突延宕以及特朗普政府对华加征 145% 关税的政策落地，使得全球供应链面临重构压力。黄金作为传统避险资产，在不确定性中成为 资金的 "避风港"。例如，特朗普关税政策落地后，金价一度跳升，尽管后续政策有所调整，但黄金的避险属性已被市场重新定价。 1. 关税政策的反噬效应 特朗普的 "对等关税" 政策导致美国进口成本上升，企业盈利承压。经济学家警告，若政策持续，2025年美国 GDP 可能下降 4%，陷入技术性衰退。零售 业、休闲酒店业就业数据转弱，显示关税已对实体经济造成实质性冲击。与此同时，美国消费者信心指数降至 52.2，未来 ...

Investment Rating - The report maintains a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualan Biological Engineering, and others [4]. Core Viewpoints - The report highlights the investment opportunities in innovative drugs against the backdrop of global asset rebalancing, particularly focusing on KRAS G12C mutation in non-small cell lung cancer (NSCLC) [2][8]. - It emphasizes the potential for KRAS G12C inhibitors to advance to first-line treatment for NSCLC, with an estimated 30% of KRAS mutations in NSCLC being of the G12C subtype, leading to approximately 30,000 new cases annually in China [5][17]. Summary by Sections 1. Industry Viewpoints and Investment Recommendations - KRAS G12C inhibitors are progressing towards first-line treatment for NSCLC, with current standard therapies being PD1 ± chemotherapy [18]. - The report suggests focusing on innovative drugs, particularly in the context of increased liquidity and risk appetite in the market, with significant data releases expected from major conferences [6][32]. 2. Pharmaceutical Industry Market Performance - The pharmaceutical sector saw a 1.01% increase, slightly underperforming the CSI 300 index by 1.00 percentage points [39]. - Sub-sectors such as drug packaging and medical devices performed well, while innovative drugs lagged behind [39]. 3. Company Dynamics - Notable company activities include the approval of new drugs and clinical trial advancements, such as the successful Phase III trials for AstraZeneca's Breztri and Genmab's Epcoritamab [46]. - Companies like Junshi Biosciences and Innovent Biologics are highlighted for their leading positions in the KRAS G12C inhibitor market [22][23]. 4. Industry Dynamics - The report discusses the impact of patent expirations on raw material demand, projecting a significant increase in sales due to the expiration of patents for top-selling small molecule drugs [35]. - It also notes the improvement in demand for raw materials and the end of inventory destocking phases, suggesting a positive outlook for the raw material sector [35].